Fmr LLC Has $693,000 Stock Position in Inari Medical, Inc. (NASDAQ:NARI)

FMR LLC decreased its stake in shares of Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 61.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,815 shares of the company's stock after selling 26,821 shares during the period. FMR LLC's holdings in Inari Medical were worth $693,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC lifted its position in shares of Inari Medical by 7.7% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 4,852 shares of the company's stock worth $234,000 after purchasing an additional 348 shares in the last quarter. Arizona State Retirement System boosted its position in Inari Medical by 2.5% in the 2nd quarter. Arizona State Retirement System now owns 14,602 shares of the company's stock valued at $703,000 after buying an additional 358 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Inari Medical by 83.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company's stock valued at $46,000 after buying an additional 435 shares during the period. GAMMA Investing LLC raised its position in shares of Inari Medical by 67.2% during the third quarter. GAMMA Investing LLC now owns 1,177 shares of the company's stock worth $49,000 after acquiring an additional 473 shares during the last quarter. Finally, KBC Group NV lifted its stake in shares of Inari Medical by 39.0% during the third quarter. KBC Group NV now owns 1,774 shares of the company's stock valued at $73,000 after acquiring an additional 498 shares during the period. Institutional investors own 90.98% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Canaccord Genuity Group lifted their price objective on Inari Medical from $71.00 to $74.00 and gave the stock a "buy" rating in a research report on Tuesday, October 29th. Piper Sandler raised their target price on shares of Inari Medical from $50.00 to $52.00 and gave the company a "neutral" rating in a research note on Tuesday, October 29th. Robert W. Baird boosted their price target on shares of Inari Medical from $66.00 to $67.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 29th. Stifel Nicolaus initiated coverage on shares of Inari Medical in a report on Tuesday, September 17th. They issued a "hold" rating and a $50.00 price objective on the stock. Finally, Truist Financial lifted their target price on shares of Inari Medical from $50.00 to $63.00 and gave the stock a "hold" rating in a report on Wednesday. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $61.80.

Insider Buying and Selling

In other news, CEO Andrew Hykes sold 3,000 shares of the stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the sale, the chief executive officer now owns 445,310 shares of the company's stock, valued at $22,265,500. This represents a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William Hoffman sold 40,000 shares of the firm's stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total transaction of $1,800,800.00. Following the sale, the director now owns 601,233 shares in the company, valued at approximately $27,067,509.66. The trade was a 6.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 203,000 shares of company stock valued at $10,362,000. 10.60% of the stock is owned by company insiders.

Inari Medical Price Performance

Shares of NASDAQ NARI traded down $1.13 during midday trading on Wednesday, reaching $55.03. 1,297,859 shares of the stock were exchanged, compared to its average volume of 992,969. Inari Medical, Inc. has a 12 month low of $36.73 and a 12 month high of $67.10. The company has a market capitalization of $3.22 billion, a price-to-earnings ratio of -40.76 and a beta of 0.97. The business has a 50-day simple moving average of $49.30 and a two-hundred day simple moving average of $48.04.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.